Immunohistochemical evaluation and flow cytometry results demonstrated an increased population of CD4+ and CD8+ T cells and a reduction in T-regs in the TME of mice treated with hNPs plus photoinduced therapy, which supports the hypothesis that imatinib-loaded hNPs inhibit the suppressive effects of T-regs and hence protect tumor antigen presentation and cytotoxic T cells. Here, CD4 is linked to neoplasm.